Zydus receives final approval from the USFDA for Febuxostat Tablets

Zydus receives final approval from the USFDA for Febuxostat Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India.

FPJ Web DeskUpdated: Tuesday, January 10, 2023, 03:14 PM IST
article-image
Zydus receives final approval from the USFDA for Febuxostat Tablets | File/ Representative image

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Febuxostat Tablets, 40 mg and 80 mg (USRLD: Uloric Tablets).

Febuxostat tablets are indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India.

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).

The group now has 340 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.

RECENT STORIES

India’s External Debt Rises To USD 747.2 Billion By June 2025: RBI

India’s External Debt Rises To USD 747.2 Billion By June 2025: RBI

US Report Slams Sri Lanka's 'Inconsistent' Investment Climate, Cites Adani's $400 Million Exit

US Report Slams Sri Lanka's 'Inconsistent' Investment Climate, Cites Adani's $400 Million Exit

Office Space Leasing Jumps 35% Across 8 Major Cities In July-September: C&W

Office Space Leasing Jumps 35% Across 8 Major Cities In July-September: C&W

Govt Keeps Interest Rates On Small Savings Schemes Unchanged

Govt Keeps Interest Rates On Small Savings Schemes Unchanged

LG Electronics India Set To Launch Its Mega IPO On October 7

LG Electronics India Set To Launch Its Mega IPO On October 7